gw501516

<p>GW-501516 or Cardarine(1) as it&rsquo;s called was developed in the 1990s by a joint effort of two pharmaceuticals powerhouses GlaxoSmithKline and Ligand Pharmaceuticals. Originally set in motion at clinical developmental stages as a drug to forestall cardiovascular diseases especially tumor formation in different parts of the body like breasts, colon, and prostate.</p>

<p>Cardarine (GW501516) is a PPAR receptor agonist invented by Ligand Pharmaceuticals and GlaxoSmithKline in the 1990s. Cardarine was originally developed to treat obesity, diabetes, lipid strain, and cardiovascular diseases. Those who run blood work when using cardarine will notice that their cholesterol levels improve substantially.</p>

<p>&nbsp;</p> <p>Seems like there&rsquo;s always something new in the fitness game, and despite the fact that GW-501516 is now under the spotlight, it&rsquo;s actually been on the market since the early 1990s. Bodybuilders even call it the ultimate performance enhancer. Simply said, it&rsquo;s a chemical substance that activates the peroxisome proliferator activator receptor delta, or for short &ndash; PPAR delta. And if you&rsquo;re wondering what that is &ndash; it&rsquo;s a transcription factor that increases the expression of multiple different genes.</p>

<p>Cardarine (GW-501516) first was developed in the early 1990&rsquo;s by Ligand and GlaxoSmithKline as an anti-tumor drug.&nbsp; They also found out it worked well for lipid/heart health during the early trials and then how effective it was for endurance, diabetes, and getting rid of fat.</p>

<p>GW501516 (GW1516 or GSK-516) is often a drug that acts as a PPARd modulator. GW 501516 activates AMP-activated protein kinase and stimulates glucose uptake in skeletal muscle tissue, and GW 501516 has been demonstrated to reverse metabolic abnormalities in obese guys with pre-diabetic metabolic syndrome, probably by stimulating fatty acid oxidation.</p>

<p>Cardarine also known by GW501516, is a chemical that has been developed by conjoint research of Ligand Pharmaceuticals and Glaxo Smith Kline in 1992.</p>